SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — History and Physical — Edward W. Brooke — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Edward W. Brooke |
|---|
| Date of birth | 1919-10-26 |
|---|
| Identifiers | MRN HR-ML014-SYN-TD; SSN (made up) 000-14-5063 |
|---|
| Document date | 2003-01-13 |
|---|
| Author | Howard Bellamy, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Visit
First visit to establish shared care for breast cancer on adjuvant tamoxifen, fourteen weeks after bilateral mastectomy and right axillary dissection [S]
History of Present Illness
This fictional modern episode addresses the presenting concerns below. [S]
- Wants his breast cancer follow-up and tamoxifen managed close to home after his surgery and the start of tamoxifen at another hospital. [S]
- Had not known that men could get breast cancer and dismissed his first symptom as aging or a strained muscle; wants to understand his risk of recurrence and what it means for his family. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Edward William Brooke III was born in Washington, D.C., on October 26, 1919. [D]
- Brooke was elected attorney general of Massachusetts in 1962 and re-elected in 1964, and in 1966 became the first African American elected to the U.S. Senate by popular vote; he served as a Republican senator from Massachusetts from January 3, 1967, to January 3, 1979. [D]
- In a CNN interview aired on June 11, 2003, Brooke said that in September 2002 he felt discomfort in his right breast, which he dismissed as aging, possible muscle strain, or gas; that he then had a mammogram, a sonogram, and a needle biopsy, which found a malignant tumor; that his breasts had never before been examined by a doctor; and that he had not thought men got breast cancer. [D]
- In the same interview Brooke said he had to be operated on for breast cancer, that the cancer had spread to his lymph nodes, and that all of the lymph nodes on his right side were removed. [D]
- An Associated Press report of June 11, 2003, said that Brooke, 83, had been diagnosed with breast cancer in September, had a double mastectomy, and was free of the cancer, and that he was encouraging men to examine themselves and urging insurers to cover mammograms for men. [D]
- In the 2003 interview Brooke described himself as not a smoker or a drinker and said he exercised and ate fairly good food. [D]
2 later historical claims are omitted because they describe events after the index age. See the teaching note.
Past Medical History
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|
| September 2002 | Breast cancer of the right breast in a man, diagnosed after he noticed discomfort in the right breast; mammogram, sonogram, and needle biopsy; he had never had a chest examination by a doctor before | D (CLM-0003) |
| 2002 | Operation for breast cancer, reported as a double mastectomy, with removal of the lymph nodes on the right side, to which the cancer had spread | D (CLM-0004, CLM-0005) |
Family History
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
Social History
- Occupation: retired from public office and law; writes, speaks, and serves on boards [S]
- Never smoker; does not drink alcohol; walks and exercises most days and eats a balanced diet [S]
- Lives in his own home with his spouse; independent; drives [S]
- Supports: family and a wide circle of friends and former colleagues [S]
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years) | One tablet once daily | Oral route | 2002-10-28 | active | S |
Review of Systems
Positive for the concerns in the history of present illness. Alert, articulate, and courteous; prefers to keep his diagnosis private for now and asks direct questions about his treatment. Mood good; PHQ-9 minimal at the first visit. No other systems reported as affected in this synthetic episode. [S]
General Status
Alert and engaged. Independent in all activities and instrumental activities of daily living; full shoulder movement on both sides after surgery. Walks 30 to 40 minutes most days. [S]
Physical Exam
Vital signs recorded on 2003-01-13; see the Vital Signs section. Mental status: Alert, articulate, and courteous; prefers to keep his diagnosis private for now and asks direct questions about his treatment; Mood good; PHQ-9 minimal at the first visit. The physical examination is limited to the findings relevant to this synthetic episode. [S]
Vital Signs
| Date | Measure | Value | Unit | Provenance |
| 2003-01-13 | Body height | 183 | cm | S |
| 2003-01-13 | Body weight | 81.6 | kg | S |
| 2003-01-13 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 2003-01-13 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2003-01-13 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2003-01-13 | Heart rate | 70 | /min | S |
| 2003-01-13 | Respiratory rate | 14 | /min | S |
| 2003-01-13 | Body temperature | 36.6 | Cel | S |
| 2003-01-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2003-01-13 | Hemoglobin [Mass/volume] in Blood | 13.8 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2003-01-13 | Leukocytes [#/volume] in Blood by Automated count | 6.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2003-01-13 | Platelets [#/volume] in Blood by Automated count | 214 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2003-01-13 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2003-01-13 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2003-01-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2003-01-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1998)/1.73 sq M | 71 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2003-01-13 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2003-01-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | 7-55 U/L | Normal | S |
| 2003-01-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 | U/L | 8-48 U/L | Normal | S |
| 2003-01-13 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 76 | U/L | 40-129 U/L | Normal | S |
| 2003-01-13 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2003-01-13 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2003-01-13 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 24 | ng/mL | 30-100 ng/mL | Low | S |
| 2003-01-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | | | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast cancer | active | confirmed |
C50.121 | S — Synthetic tumor size, grade, receptor status, and stage; the diagnosis, the right side, the operation, and the spread to lymph nodes are from his public account (D). |
| Estrogen receptor-positive status of the breast cancer | active | confirmed |
Z17.0 | S — Synthetic receptor result; his tumor biology was not made public. |
| Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health review | active | confirmed |
Z79.810 | S — Synthetic adjuvant therapy in the modern episode. |
| Absence of both breasts after bilateral mastectomy | active | confirmed |
Z90.13 | S — The double mastectomy is reported publicly (D); the coding is synthetic. |
Assessment
- Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast cancer: active, confirmed [S]
- Estrogen receptor-positive status of the breast cancer: active, confirmed [S]
- Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health review: active, confirmed [S]
- Absence of both breasts after bilateral mastectomy: active, confirmed [S]
Plan of Treatment
- Medical oncology consultation to take over adjuvant endocrine therapy, confirm that no further adjuvant treatment is needed, and arrange germline genetic testing. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025) [S]
- Tamoxifen 20 mg daily for an initial five years, with venous thromboembolism symptoms, mood, hot flashes, sexual side effects, adherence, and interacting medicines reviewed at every visit. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) [S]
- Genetic counseling and germline multigene panel testing (including BRCA2, BRCA1, PALB2, CHEK2, and ATM), with a letter for first-degree relatives explaining the result. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024;42(5):584-604 (2024) [S]
- Bone health: DXA at baseline, vitamin D repletion, dietary calcium, and weight-bearing exercise; bone-modifying drugs only for osteoporosis, not to prevent recurrence. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) [S]
- Survivorship surveillance: cancer-related history and examination of both sides of the chest wall and both axillae every 3 to 6 months for 3 years, then every 6 to 12 months to 5 years, then yearly; no routine imaging, blood tests, or tumor markers without symptoms; lymphedema checks. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) [S]
- Distress screening at each visit, at least 150 minutes of activity a week, and a written survivorship care plan. Guideline: Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) [S]
- Referral to medical oncology, Mei-Ling Cho, MD, ordered 2003-01-13 [S]